Outcomes of trimethoprim / sulfamethoxazole treatment for ocular toxoplasmosis in Congolese patients

Nadine Nsiangani Lusambo, Dieudonné Kaimbo Wa Kaimbo, Dieudonné Mumba Ngoyi Mumba, Alejandra de-la-Torre

Research output: Contribution to journalResearch Articlepeer-review


Background: Ocular toxoplasmosis (OT) is the leading cause of infectious posterior uveitis in several areas worldwide. The combination of Trimethoprim/Sulfamethoxazole (TMP/SMX) has been presented as an attractive alternative to the “classic’ treatment therapy (Pyrimethamine/Sulfadiazine). Methods: A prospective study was carried out between February 2020 and September 2021 in 2 ophthalmic centers in Kinshasa. This study aimed to describe TMP/SMX treatment outcomes for OT in a cohort of immunocompetent Congolese patients. Results: 54 patients were included, with a mean age at presentation of 37.5 ± 13.6 years old and a Male-Female ratio of 1.45:1. Three patients (5.6%) presented a recurrence during the follow-up period. At the end of the follow-up, improvement in VA and resolution of inflammation concerned 75.9% and 77.5% of patients, respectively. Cataracts (3.7%), macular scars (3.7%), and vitreous opacities (3.7%) were the principal causes of non-improvement in VA. Treatment-related adverse events were present in 10 patients (18.5%); gastrointestinal (14.8%) and dermatological (3.7%) adverse events were the most frequent. Dermatological adverse events led to discontinuation of treatment. Conclusion: TMP/SMX regimen appears to be a safe and effective treatment for OT in Congolese patients. The low cost and the accessibility of the molecules make this regimen an option for treating OT in resource-limited countries.

Translated title of the contributionResultados del tratamiento con trimetoprim / sulfametoxazol para la toxoplasmosis ocular en pacientes congoleños
Original languageEnglish (US)
Article number440
Pages (from-to)1-8
Number of pages8
JournalBMC Ophthalmology
Issue number1
StatePublished - Oct 31 2023

All Science Journal Classification (ASJC) codes

  • Ophthalmology


Dive into the research topics of 'Outcomes of trimethoprim / sulfamethoxazole treatment for ocular toxoplasmosis in Congolese patients'. Together they form a unique fingerprint.

Cite this